Litcius/Paper detail

Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer

Sanne C.F.A. Huijberts, Robin M.J.M. van Geel, Emilie M.J. van Brummelen, Frans L. Opdam, Serena Marchetti, Neeltje Steeghs, Saskia Pulleman, Bas Thijssen, Hilde Rosing, Kim Monkhorst, Alwin D. R. Huitema, Jos H. Beijnen, René Bernards, Jan H.M. Schellens

2020Cancer Chemotherapy and Pharmacology44 citationsDOIOpen Access PDF

Topics & Concepts

LapatinibMedicineTrametinibKRASRashColorectal cancerInternal medicineLung cancerDosingCancerOncologyPancreatic cancerPharmacokineticsPharmacologyGastroenterologyBreast cancerMAPK/ERK pathwayBiologyTrastuzumabKinaseCell biologyLung Cancer Treatments and MutationsColorectal Cancer Treatments and StudiesMelanoma and MAPK Pathways
Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer | Litcius